{"entity":{"id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of DB-1419 in advanced solid tumours, run by DualityBio Inc., now recruiting.","summary":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06554795 by DualityBio Inc., with 360 participants planned, started 2024-09-03 and due to reach its primary completion in 2027-02. Interventions recorded: DB-1419.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06554795","url":"https://clinicaltrials.gov/study/NCT06554795"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["dualitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06554795","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","enrolled":360,"outcomes":[]},"route":"/trials/nct06554795/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}